Iron Sucrose Safety Profile
Iron sucrose (Venofer) is generally safe and well-tolerated with a favorable adverse event profile compared to other intravenous iron formulations, though it requires slower infusion times and lower maximum single doses than newer agents. 1, 2
Key Safety Considerations
Hypersensitivity and Infusion Reactions
Iron sucrose has the lowest reported adverse event rate among IV iron formulations 3. Serious hypersensitivity reactions occur in <0.1% of patients 1, with mild infusion reactions occurring in approximately 1% 1. The most common adverse effects are:
- Nausea (2.9%) - most frequent side effect 4
- Mild injection site reactions
- Transient taste perversion 5
Anaphylaxis is extremely rare - a retrospective study of 238 patients receiving total dose infusions reported zero cases of anaphylaxis 4. This contrasts sharply with older high molecular weight iron dextran formulations that had adverse event rates up to 28% 6.
Administration Protocol to Minimize Reactions
Per 2026 consensus guidelines 1:
Before infusion:
- Verify correct formulation and dose
- Check for HSR risk factors
- Ensure secure IV access
- Inform patient about possible skin staining
During infusion:
- Start slowly and monitor continuously for 5-10 minutes
- Reassess cannula site every 5-10 minutes
- Maximum single dose: 500 mg over ≥220 minutes 1
- Observe patient throughout infusion
Hypophosphatemia Risk
Iron sucrose has minimal hypophosphatemia risk compared to ferric carboxymaltose. The FERWON-IDA trial demonstrated only 2.3% incidence with iron sucrose versus 3.9% with ferric derisomaltose 1. This makes iron sucrose preferable for patients requiring repeated infusions or those with risk factors for phosphate depletion.
Special Populations
Pregnancy
Iron sucrose is safe in the second and third trimesters 2. Published data show:
- No adverse developmental outcomes in randomized controlled studies 2
- Maternal adverse events similar to non-pregnant adults 2
- Critical caveat: Severe hypersensitivity reactions can cause fetal bradycardia, particularly in second/third trimester 2
- Insufficient data for first trimester use 2
Recent 2026 data confirms excellent tolerability with rapid hematologic correction and favorable neonatal outcomes when used between 26-32 weeks gestation 7.
Pediatrics
Safety established in children ≥2 years for maintenance therapy 2. However:
- Not FDA-approved for replacement therapy in pediatric CKD 2
- Effective and well-tolerated in children with intestinal failure as young as 4 months 8
- Warning: Five premature infants (<1,250g) developed necrotizing enterocolitis; two died. No causal relationship established, but use extreme caution in very low birth weight infants 2
Lactation
Safe during breastfeeding - iron sucrose is present in breast milk but no adverse reactions reported in breastfed infants 2. Monitor infants for GI toxicity (constipation, diarrhea) 2.
Elderly
No dose adjustment needed - 40% of post-marketing safety study patients were ≥65 years with no safety differences versus younger patients 2. Use caution given higher likelihood of comorbidities 2.
Rare but Serious Adverse Events
Severe Thrombocytopenia
A 2026 case report documented severe thrombocytopenia (platelets dropping to 11 × 10³/µL) after two doses of iron sucrose 9. While extremely rare, this underscores the need for hematologic monitoring beyond just hemoglobin.
Circulatory Collapse
Severe hypotension and shock can occur, particularly dangerous in pregnancy due to risk of fetal bradycardia 2.
Comparative Safety
Iron sucrose ranks as the safest IV iron formulation based on adverse event frequency 3:
- Iron sucrose - lowest adverse events
- Low molecular weight iron dextran and ferric gluconate - intermediate
- High molecular weight iron dextran - highest (no longer available)
However, iron sucrose requires multiple visits due to 500 mg maximum single dose versus 1000-2000 mg for newer formulations 1, 6.
Clinical Monitoring Recommendations
Do not routinely screen for hypophosphatemia unless patient has 1:
- Multiple/repeated infusions planned
- High cumulative iron exposure
- Baseline risk factors (malnutrition, antiresorptive therapy, low baseline phosphate)
- Symptoms of phosphate depletion (worsening fatigue with myalgias/bone pain)
Monitor hemoglobin response at 4-6 weeks - expect mean increase of 1.9 g/dL in pediatric IF patients 8 and 2.1 g/dL in adults 4.
Key Pitfall to Avoid
Do not confuse Fishbane-like symptoms with anaphylaxis 1. Fishbane reactions (~1% incidence) present with sudden chest/back tightness, myalgia, mild hypotension but no respiratory compromise or rash. These are self-limited and resolve with stopping infusion. True anaphylaxis (<0.1%) involves respiratory distress, severe hypotension, and requires immediate treatment.